Clinical trials: Malignancies Multiple
Non-Small Cell Lung Cancer
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT06883630
- Testing
- RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- RemeGen Co., Ltd.
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
The purpose of this study is to evaluate the efficacy and safety of Amphinex induced PCI of bleomycin ('PC-A11') with superficial and/or interstitial laser light application in patients with recurrent SCCHN.
- Trial name
- NCT01606566
- Testing
- Amphinex induced PCI of bleomycin
- Where
- 10 sites in France, Germany and 4 more
- Volunteers
- 26 people
- Sponsor
- PCI Biotech AS
Multiple Myeloma
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
This observational study will observe the degree of the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of…
- Trial name
- NCT01021592
- Testing
- bortezomib
- Volunteers
- 140 people
- Sponsor
- Janssen Korea, Ltd., Korea
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Lymphoma
Evaluation of KX2-391 in Patients With Advanced Malignancies
The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.
- Trial name
- NCT00658970
- Testing
- KX2-391
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Athenex, Inc.
Multiple Myeloma
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of bortezomib in participants with multiple myeloma who have previously responded to a bortezomib based therapy.
- Trial name
- NCT00431769
- Testing
- Bortezomib
- Where
- 38 sites in Austria, Belgium and 6 more
- Volunteers
- 130 people
- Sponsor
- Janssen-Cilag International NV
Advanced Solid Tumor
A Study of GFH018 in Patients With Advanced Solid Tumors
This is the first- in human study of GFH018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration.
- Trial name
- NCT05051241
- Testing
- GFH018
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
Advanced Malignant Thyroid Tumors
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent radioactive iodine , or combination with surgery for treatment of…
- Trial name
- NCT00902122
- Testing
- rAd-p53 gene, surgery, p53 gene therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
B-cell Non Hodgkin Lymphoma
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
- Trial name
- NCT05338931
- Testing
- AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
- Where
- South Korea
- Volunteers
- 82 people
- Sponsor
- AbClon
Glioblastoma Multiforme
APG101 in Glioblastoma
This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients suffering from a malignant brain tumor called glioblastoma having a first or second progression can be included.
- Trial name
- NCT01071837
- Testing
- APG101, Blood drawing
- Where
- 21 sites in Austria, Germany
- Volunteers
- 84 people
- Sponsor
- Apogenix GmbH
Chronic Myelogenous Leukemia in Chronic Phase
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).
- Trial name
- MACS1428 (NCT01227577)
- Testing
- Nilotinib
- Where
- 32 sites in United States
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment…
- Trial name
- NCT00574288
- Testing
- Part 1: Daratumumab, Part 2: Daratumumab, Methylprednisolone
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 104 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT04244656
- Testing
- CTX120
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 26 people
- Sponsor
- CRISPR Therapeutics AG
B-cell Non Hodgkin Lymphoma
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT06392477
- Testing
- SAR448501
- Where
- 16 sites in Australia, Serbia and 3 more
- Volunteers
- 96 people
- Sponsor
- Sanofi
Leukemia, T-Cell
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced…
- Trial name
- NCT00095381
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- 24 sites in United States, Georgia
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Multiple Myeloma
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00229203
- Testing
- Plitidepsin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- PharmaMar
Lymphoma, Non-Hodgkin
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Comparison of rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab or the Bexxar Therapeutic Regimen, formerly called Iodine-131 Anti-B1 Antibody) in subjects with follicular non…
- Trial name
- NCT00268983
- Testing
- Tositumomab and Iodine I 131 Tositumomab, Rituximab
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Advanced Metastatic Castration Resistant Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT06609005
- Testing
- INV-9956
- Where
- 22 sites in United States, China
- Volunteers
- 84 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.